scholarly journals Single-objective high-resolution light sheet fluorescence microscopy for standard biological sample geometries

2021 ◽  
Author(s):  
Knut Drescher ◽  
Stoyan Yordanov ◽  
Konstantin Neuhaus ◽  
Raimo Hartmann ◽  
Francisco Diaz-Pascual ◽  
...  
Keyword(s):  
High Resolution ◽  
Fluorescence Microscopy ◽  
Biological Sample ◽  
Light Sheet ◽  
Light Sheet Fluorescence Microscopy ◽  
Single Objective

High resolution 3D imaging of primary and secondary tumor spheroids using multicolor multi-angle Light Sheet Fluorescence Microscopy (LSFM)

2019 ◽  
Author(s):  
Stylianos E. Psycharakis ◽  
Evangelos Liapis ◽  
Athanasios Zacharopoulos ◽  
Mariam-Eleni Oraiopoulou ◽  
Chrysoula Aivalioti ◽  
...  
Keyword(s):  
High Resolution ◽  
Fluorescence Microscopy ◽  
3D Imaging ◽  
Light Sheet ◽  
Tumor Spheroids ◽  
Secondary Tumor ◽  
Light Sheet Fluorescence Microscopy

scholarly journals High-resolution live imaging of plant growth in near physiological bright conditions using light sheet fluorescence microscopy

2011 ◽  
Vol 68 (2) ◽  
pp. 377-385 ◽  
Author(s):  
Alexis Maizel ◽  
Daniel von Wangenheim ◽  
Fernán Federici ◽  
Jim Haseloff ◽  
Ernst H.K. Stelzer
Keyword(s):  
High Resolution ◽  
Plant Growth ◽  
Fluorescence Microscopy ◽  
Light Sheet ◽  
Live Imaging ◽  
Light Sheet Fluorescence Microscopy

scholarly journals Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Stefanie Schwinn ◽  
Zeinab Mokhtari ◽  
Sina Thusek ◽  
Theresa Schneider ◽  
Anna-Leena Sirén ◽  
...  
Keyword(s):  
Fluorescence Microscopy ◽  
Tumor Growth ◽  
Intensive Therapy ◽  
Xenograft Model ◽  
Light Sheet ◽  
Tumor Control ◽  
Orthotopic Model ◽  
Group 3 ◽  
Light Sheet Fluorescence Microscopy

AbstractMedulloblastoma is the most common high-grade brain tumor in childhood. Medulloblastomas with c-myc amplification, classified as group 3, are the most aggressive among the four disease subtypes resulting in a 5-year overall survival of just above 50%. Despite current intensive therapy regimens, patients suffering from group 3 medulloblastoma urgently require new therapeutic options. Using a recently established c-myc amplified human medulloblastoma cell line, we performed an in-vitro-drug screen with single and combinatorial drugs that are either already clinically approved or agents in the advanced stage of clinical development. Candidate drugs were identified in vitro and then evaluated in vivo. Tumor growth was closely monitored by BLI. Vessel development was assessed by 3D light-sheet-fluorescence-microscopy. We identified the combination of gemcitabine and axitinib to be highly cytotoxic, requiring only low picomolar concentrations when used in combination. In the orthotopic model, gemcitabine and axitinib showed efficacy in terms of tumor control and survival. In both models, gemcitabine and axitinib were better tolerated than the standard regimen comprising of cisplatin and etoposide phosphate. 3D light-sheet-fluorescence-microscopy of intact tumors revealed thinning and rarefication of tumor vessels, providing one explanation for reduced tumor growth. Thus, the combination of the two drugs gemcitabine and axitinib has favorable effects on preventing tumor progression in an orthotopic group 3 medulloblastoma xenograft model while exhibiting a favorable toxicity profile. The combination merits further exploration as a new approach to treat high-risk group 3 medulloblastoma.

Sign in / Sign up

Export Citation Format

Share Document